Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.…
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
Polaryx Therapeutics (NASDAQ: PLYX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 1.330 USD on 20 November 2026. Its 52-week range is 1.301 USD to 48.91 USD: the price is 97.3% below the high and 2.3% above the low.
Its market capitalisation is 62.97M USD.
Polaryx Therapeutics reports return on equity of -196.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 8.44M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.